Dronedarone
Class
Antiarrhythmics
Subclass
Class III antiarrhythmics
Substance name
Dronedarone
Brand names
Multaq®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Treatment
AF • Paroxysmal or persistent, maintenance of rhythm control
Secondary prevention
Secondary prevention of atrial flutter • Paroxysmal, associated with disabling symptoms • Off-label
Indications for use
Labeled indications
Adults
Off-label indications
Adults
Safety risks
Boxed warnings
Exacerbation of HF
HF
Contraindications
Hypersensitivity to dronedarone or any of its components
Bradycardia <50 bpm
Liver or lung toxicity related to the previous use of amiodarone
QTc interval >500 ms or PR interval >280 ms
Second or third-degree AV block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker)
Concomitant use of a strong CYP3A inhibitor
Concomitant use of drugs or herbal products that prolong the QT interval and may induce torsade de pointes
Concomitant use of erythromycin
Warnings and precautions
Cardiovascular risk
Hepatocellular injury
HF
Hypokalemia, hypomagnesemia
ILD
Prolonged QT interval
Specific populations
Renal impairment
eGFR 30-50 mL/min/1.73 m²
eGFR 10-30 mL/min/1.73 m²
eGFR < 10 mL/min/1.73 m²
Renal replacement therapy
Continuous renal replacement
Intermittent hemodialysis
Peritoneal dialysis
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: D
Breastfeeding
Acceptable for use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource